Skip to main content
Hansa Biopharma logo

Hansa Biopharma — Investor Relations & Filings

Ticker · HNSA ISIN · SE0002148817 LEI · 549300LLEO25ZJJ3NT91 ST Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2018-09-27 Regulatory Filings
Country SE Sweden
Listing ST HNSA

About Hansa Biopharma

https://www.hansabiopharma.com/

Hansa Biopharma is a commercial-stage biopharmaceutical company that develops and commercializes treatments for rare immunologic diseases. The company's core focus is its proprietary antibody-cleaving enzyme technology platform, designed to target and inactivate immunoglobulin G (IgG) antibodies. This approach aims to inhibit harmful IgG-mediated immune responses. Its lead product, imilfidase, is used to enable kidney transplantation in highly sensitized patients who have a low probability of finding a compatible donor. The company is also advancing its enzyme technology to address unmet medical needs in other therapeutic areas, including acute autoimmune diseases, gene therapy, and oncology, where IgG antibodies can be a barrier to treatment or a driver of the disease.

Recent filings

Filing Released Lang Actions
Hansa Medical Reports Positive Final Top Line Results from Two Phase 2 Studies of Imlifidase for Kidney Transplantation
Regulatory Filings Classification · 95% confidence The document is a press release announcing positive top-line results from Phase 2 clinical studies for a drug called Imlifidase. It details efficacy, safety, and future regulatory filing plans (BLA/MAA submissions in Q4 2018 or Q1 2019). It also announces a conference call to discuss these results. This content structure—announcing key results and future regulatory steps—is characteristic of an Earnings Release (ER) or a general press release announcing significant operational/clinical milestones. Since it focuses purely on clinical trial results and future regulatory plans rather than comprehensive financial performance for a reporting period (like a 10-Q or 10-K), and it is an initial announcement of results, 'ER' (Earnings Release) is the most appropriate classification, even though the results are clinical rather than purely financial earnings. It is not a full transcript (CT), a formal annual report (10-K), or a presentation (IP). The final paragraph mentions the information is submitted for publication pursuant to the EU Market Abuse Regulation, confirming it is a regulatory announcement of material information.
2018-09-27 English
Hansa Medical utser Vincenza Nigro till Vice President, Global Medical Affairs
Board/Management Information Classification · 98% confidence The document announces the appointment of a new executive, Vincenza Nigro, to the position of Vice President, Global Medical Affairs. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of Board/Management Information (MANG). The text is a press release format, not a comprehensive financial report (like 10-K or IR) or a general regulatory filing (RNS).
2018-09-17 Swedish
Hansa Medical Announces Appointment of Vincenza Nigro as Vice President, Global Medical Affairs
Board/Management Information Classification · 98% confidence The document is an official press release from Hansa Medical AB announcing the appointment of a new executive, Vincenza Nigro, as Vice President, Global Medical Affairs. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of 'Board/Management Information'. The document structure (headline announcing the appointment, date, company details, executive background, and contact information) confirms it is a management announcement, not a financial report (like 10-K or IR) or a general regulatory filing (RNS).
2018-09-17 English
Emission och återköp av C-aktier för incitamentsprogram
Share Issue/Capital Change Classification · 99% confidence The document is a press release dated September 6, 2018, titled 'Emission och återköp av C-aktier för incitamentsprogram' (Issuance and repurchase of C-shares for incentive program). It details the board's decision to conduct a new issuance of C-shares followed immediately by a repurchase of those same shares, all related to the LTIP 2018 incentive program. This action directly concerns the company's capital structure, specifically the issuance and subsequent handling of shares, which falls under Capital/Financing Update (CAP) or Share Issue/Capital Change (SHA). Since the core action is the issuance and repurchase of shares related to an employee program, 'Share Issue/Capital Change' (SHA) is the most precise fit, as it covers changes in capital structure via share issuance/repurchase, although 'CAP' is also relevant. Given the specific nature of issuing and repurchasing shares, SHA is preferred over the broader CAP. The document is not a general regulatory filing (RNS) because it describes a specific corporate action.
2018-09-06 Swedish
Issue and repurchase of class C shares for incentive program
Transaction in Own Shares Classification · 98% confidence The document is a press release dated September 6, 2018, announcing the 'Issue and repurchase of class C shares for incentive program'. This action directly relates to the company's own stock transactions, specifically the issuance and subsequent repurchase of shares related to an incentive program (LTIP 2018). This fits the definition of 'Transaction in Own Shares' (POS), which covers share repurchase or issuance activities by the company itself. It is not a general financing update (CAP) as it is highly specific to an employee incentive scheme involving immediate repurchase, nor is it a general share issue (SHA) which usually implies raising capital from the public.
2018-09-06 English
Increase of number of shares and votes in Hansa Medical AB (publ)
Share Issue/Capital Change Classification · 98% confidence The document is a press release dated July 31, 2018, announcing an 'Increase of number of shares and votes in Hansa Medical AB (publ)' due to the completion of a warrant program, resulting in the issuance of 50,000 ordinary shares. This directly relates to a change in the company's capital structure (share count and registered capital). This aligns perfectly with the definition for 'Share Issue/Capital Change' (SHA), which covers announcements regarding new share issues or capital changes. It is not a general earnings release (ER), a full annual report (10-K), or a dividend notice (DIV).
2018-07-31 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.